Flexion announces the nationwide availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) and full complement of field sales personnel deployed across the U.S. Read More
Read the latest news from the MassBio community! This space is for members to share company updates and press releases. Members may not post stories that are copyrighted by news publications or post sales pitches.
Flexion named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey project conducted by The Boston Globe. Read More
Asymmetrex co-sponsors Nov. 30 online RegMedNet expert panel on the state of knowledge for production and characterization of tissue stem cells used in approved therapies and experimental treatments. Read More
MA stem cell biotech company Asymmetrex proposes that its new technology for certifying the specific dose and quality of tissue stem cells used in experimental treatments would improve FDA’s efforts. Read More
Flexion receives FDA approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain Read More
Two years ago, Asymmetrex announced a first-ever technology for counting adult tissue stem cells. Now, the company reveals how counting can increase therapeutic stem cell production at reduced cost. Read More